EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How to Evaluate Fibrosis in IBD?

Helena Tavares de Sousa iD, Fernando Magro iD

Diagnostics · 27.06.2023 · 13 (13) · 2188

DOI: 10.3390/diagnostics13132188 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 27.06.2023. Verfasst von Helena Tavares de Sousa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Algarve University Hospital Center, 8500-338 Portimão, Portugal. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this review, we will describe the importance of fibrosis in inflammatory bowel disease (IBD) by discussing its distinct impact on Crohn’s disease (CD) and ulcerative colitis (UC) through their translation to histopathology. We will address the existing knowledge on the correlation between inflammation and fibrosis and the still not fully explained inflammation-independent fibrogenesis. Finally, we will compile and discuss the recent advances in the noninvasive assessment of intestinal fibrosis, including imaging and biomarkers. Based on the available data, none of the available cross-sectional imaging (CSI) techniques has proved to be capable of measuring CD fibrosis accurately, with MRE showing the most promising performance along with elastography. Very recent research with radiomics showed encouraging results, but further validation with reliable radiomic biomarkers is warranted. Despite the interesting results with micro-RNAs, further advances on the topic of fibrosis biomarkers depend on the development of robust clinical trials based on solid and validated endpoints. We conclude that it seems very likely that radiomics and AI will participate in the future non-invasive fibrosis assessment by CSI techniques in IBD. However, as of today, surgical pathology remains the gold standard for the diagnosis and quantification of intestinal fibrosis in IBD.

Schlagwörter

Stichwörter der Autor:innen

biomarkersfibrosisimaginginflammationinflammatory bowel disease

Autor:innen und Institutionen

  • Gastroenterology Department, Algarve University Hospital Center, 8500-338 Portimão, Portugal.
  • ABC-Algarve Biomedical Center, University of Algarve, 8005-139 Faro, Portugal.
  • Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal.
  • Department of Gastroenterology, São João University Hospital Center, 4200-319 Porto, Portugal.
  • CINTESIS@RISE, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal.

ORCID-Profile: Helena Tavares de Sousa, Fernando Magro

Zitieren

APA

Tavares de Sousa, H., & Magro, F. (2023). How to Evaluate Fibrosis in IBD?. Diagnostics, 13(13), 2188. https://doi.org/10.3390/diagnostics13132188

Vancouver

Tavares de Sousa H, Magro F. How to Evaluate Fibrosis in IBD?. Diagnostics. 2023;13(13):2188. doi:10.3390/diagnostics13132188

BibTeX
@article{TavaresdeSousa2023,
  author = {Tavares de Sousa, Helena and Magro, Fernando},
  title = {How to Evaluate Fibrosis in IBD?},
  journal = {Diagnostics},
  year = {2023},
  volume = {13},
  number = {13},
  pages = {2188},
  doi = {10.3390/diagnostics13132188}
}
Kostenlos starten →